Ingestible sensor company Proteus Digital Health and computer giant Oracle have integrated Proteus's digital health feedback system, which includes an ingestible pill sensor, a wearable patch, and a ...

Oracle has expanded its move into pharmaceutical innovation by investing an undisclosed “minor” sum in Proteus Digital Health, a company that has developed ingestible and wearable sensors. Proteus’ ...

After years of using its digital health feedback system in clinical trials and studies, Proteus Digital Health, and partner Otsuka Pharmaceuticals, are poised to launch the first mass market drug to ...

Oracle and Proteus Digital Health announced today that Oracle has made a strategic minority investment in Proteus, a leading digital health company. Proteus has developed ingestible and wearable ...

The “Beyond the Pill” movement marked a major milestone with the FDA’s acceptance of the first digital medicine-New Drug Application. It will pair Proteus Digital Health’s ingestible sensor platform ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its ingestible sensor for marketing as a medical device ...

The search for breakthrough drugs in the pharmaceuticals industry hinges largely on a non-scientific variable: whether patients take their meds. Too many don’t, which continues to be a major challenge ...

Forbes contributors publish independent expert analyses and insights. Robert Glatter is a New York-based physician covering public health. When a healthcare provider writes a prescription for a ...

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". TOKYO and REDWOOD CITY, Calif., Nov. 14, 2017 /PRNewswire/ -- Otsuka ...

If you have trouble remembering whether you took your pills on time, your medicine may soon have the answer for you. Pills for anything from the common cold to diabetes or cancer can be embedded with ...

Agreement will exploit Proteus’ technologies designed to provide feedback on factors such as patient physiology and compliance. Proteus Biomedical will receive $24 million worth of cash and equity ...